Latvija - latviešu - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - citaloprāms - apvalkotās tabletes - 20 mg

Latvija - latviešu - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - citaloprāms - apvalkotās tabletes - 10 mg

Latvija - latviešu - Zāļu valsts aģentūra

egis pharmaceuticals plc, hungary - citaloprāms - apvalkotās tabletes - 40 mg

Latvija - latviešu - Zāļu valsts aģentūra

glaxosmithkline biologicals s.a., belgium - a hepatīta vīruss (inaktivēts) - suspensija injekcijām - 720 elisa v/0,5 ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor - cistiskā fibroze - other respiratory system products - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 un 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - velaglucerase alfa - gošē slimība - citas gremošanas trakta un metabolisma produkti, - vpriv ir indicēts ilgstošai enzīmu aizstājterapijai (ert) pacientiem ar 1. tipa gošē slimību.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

chanelle pharmaceuticals manufacturing limited, Īrija - karprofēns - tabletes - 50 mg - suņi

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

zylavet pharmaceuticals, ungārija - praziquantelum, pyrantelum - košļājamās tabletes - kaķi

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

chanelle pharmaceuticals manufacturing ltd., Īrija - prazikvantels, pirantela embonate, febantels - tabletes - suņi

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

chanelle pharmaceuticals manufacturing ltd., Īrija - prazikvantels, pirantela embonate, febantels - tabletes - suņi